DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H1 2016" report to their offering.
Female Sexual Dysfunction Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Female Sexual Dysfunction pipeline therapeutics constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 4, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Female Sexual Dysfunction - Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects.
- Apricus Biosciences, Inc.
- Emotional Brain BV
- EndoCeutics, Inc.
- M et P Pharma AG
- Palatin Technologies, Inc.
- Re-Pharm Limited
- TherapeuticsMD, Inc.
- Valeant Pharmaceuticals International, Inc.
For more information visit http://www.researchandmarkets.com/research/wvfdvh/female_sexual